The FDA is reviewing an application by drugmaker GSK to expand the use of its RSV (respiratory syncytial virus) vaccines to Americans between 50-59 years old. The vaccine was approved last year for individuals 60 years and older. Studies have shown the vaccine to highly effective at preventing severe disease from the virus. If health officials find the vaccine to be safe and effective for people ages 50-59, it would be the first RSV vaccine approved for this age group. The FDA expects to hold the vote on June 7. Heath authorities in Europe and Japan are currently considering the vaccine for use by people in this age range who are also more vulnerable to RSV.
Full Story: CIDRAP